Updated Follow-up Analysis in the REP 401 Protocol: Treatment of HBeAg Negative Chronic HBV Infection with REP 2139 or REP 2165, Tenofovir Disoproxil Fumarate and Pegylated Interferon α-2a

被引：0
|
作者：
Bazinet, M. [1 ]
Pantea, V. [2 ]
Placinta, G. [2 ]
Moscalu, I. [3 ]
Cebotarescu, V. [2 ]
Cojuhari, L. [2 ]
Jimbei, P. [4 ]
Iarovoi, L. [2 ]
Smesnoi, V. [4 ]
Musteata, T. [4 ]
Jucov, A. [3 ]
Krawczyk, A. [5 ]
Vaillant, A. [1 ]
机构：
[1] Replicor, Montreal, PQ, Canada
[2] State Univ Med & Pharm Nicolae Testemitanu, Fac Postgrad Educ, Dept Infect Dis, Kishinev, Moldova
[3] ARENSIA Exploratory Med, Republican Clin Hosp, Phase Unit 1, Dusseldorf, Germany
[4] Infect Clin Hosp Toma Ciorba, Kishinev, Moldova
[5] Univ Klinikum Essen, Inst Virol, Essen, Germany
来源：
JOURNAL OF VIRAL HEPATITIS | 2018年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
O-018
引用
收藏
页码：14 / 14
页数：1
相关论文
共 22 条
  • [1] Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon alfa-2a
    Vaillant, A.
    Bazinet, M.
    Pantea, V.
    Placinta, G.
    Moscalu, I.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Iarovoi, L.
    Smesnoi, V.
    Musteata, T.
    Jucov, A.
    Krawczyk, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S517 - S517
  • [2] Interim follow-up analysis in the REP 401 protocol: functional control of HBeAg negative chronic HBV infection persists after withdrawal of combined therapy with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated interferon α-2a
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    HEPATOLOGY, 2017, 66 (06) : 1269A - 1269A
  • [3] Update on safety and efficacy in the REP 401 protocol: REP 2139-Mgor REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatment naive caucasian patients with chronic HBeAg negative HBV infection
    Bazinet, M.
    Pantea, V.
    Placinta, G.
    Moscalu, I.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Iarovoi, L.
    Smesnoi, V.
    Musteata, T.
    Jucov, A.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S256 - S257
  • [4] Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naive Caucasian patients with chronic HBeAg negative HBV infection
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    HEPATOLOGY, 2016, 64 (06) : 1122A - 1123A
  • [5] Establishment of High Rates of Functional Control and Reversal of Fibrosis Following Treatment of Hbeag Negative Chronic HBV Infection with REP 2139-Mg / REP 2165-Mg, Tenofovir Disoproxil Fumarate and Pegylated Interferon Alpha-2a
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    HEPATOLOGY, 2018, 68 : 234A - 235A
  • [6] Safety and Efficacy of 48 Weeks REP 2139 or REP 2165, Tenofovir Disoproxil, and Pegylated Interferon Alfa-2a in Patients With Chronic HBV Infection Naive to Nucleos(t)ide Therapy
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Dittmer, Ulf
    Krawczyk, Adalbert
    Vaillant, Andrew
    GASTROENTEROLOGY, 2020, 158 (08) : 2180 - 2194
  • [7] Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: Ongoing follow-up results from the REP 401 study
    Bazinet, Michel
    Pantea, Victor
    Placinta, Gheorghe
    Moscalu, Iurie
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Iarovoi, Liviu
    Smesnoi, Valentina
    Musteata, Tatiana
    Jucov, Alina
    Krawczyk, Adalbert
    Vaillant, Andrew
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E486 - E486
  • [8] One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S96 - S97
  • [9] Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S509 - S509
  • [10] Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Albrecht, Jeffrey
    Schmid, Peter
    Krawczyk, Adalbert
    Karimzadeh, Hadi
    Roggendorf, Michael
    Valliant, Andrew
    HEPATOLOGY, 2016, 64 : 912A - 912A
123